Histidine Supplementation for Antitumor Immunity in Colorectal Cancer

The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment. Participants with colorectal cancer in the supplementation group will: Take 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.

Trial Details

NCT ID
NCT07577505
Phase
NA
Sponsor
Jing-yuan Fang, MD, Ph. D
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Histidine
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients aged 18-80 years, regardless of sex.
  • Body mass index (BMI) ≥18.5.
  • NRS-2002 score \<3.
  • Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →